BTK
BTK (Bruton's tyrosine kinase) inhibitors are compounds that specifically target and inhibit BTK, a crucial enzyme involved in B-cell receptor signaling and the regulation of angiogenesis. BTK plays a significant role in the proliferation and survival of cancer cells, particularly in hematological malignancies. By inhibiting BTK, these compounds can disrupt angiogenesis and tumor growth, making them valuable in cancer therapy. At CymitQuimica, we offer a range of high-quality BTK inhibitors to support your research in oncology, immunology, and angiogenesis.
Found 145 products of "BTK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
ARQ 531
CAS:<p>ARQ-531: potent oral BTK inhibitor, anti-cancer potential, IC50 of 0.85/0.39 nM for WT/C481S-BTK.</p>Formula:C25H23ClN4O4Purity:98.68% - 99.63%Color and Shape:SolidMolecular weight:478.93Btk inhibitor 2
CAS:<p>Btk inhibitor 2 (BGB-3111 analog) is a BTK inhibitor.</p>Formula:C24H25N5O3Purity:99.94%Color and Shape:SolidMolecular weight:431.49AS-1763
CAS:<p>AS-1763 is an orally available and selective BTK inhibitor with an IC50 of 0.85 nM.</p>Formula:C33H31FN6O3Purity:≥95%Color and Shape:SolidMolecular weight:578.64Orelabrutinib
CAS:<p>Orelabrutinib (ICP-022) is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).</p>Formula:C26H25N3O3Purity:97.77% - 99.54%Color and Shape:SolidMolecular weight:427.49IBT6A
CAS:<p>IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.</p>Formula:C22H22N6OPurity:99.8% - 99.88%Color and Shape:SolidMolecular weight:386.45Rilzabrutinib
CAS:<p>Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).</p>Formula:C36H40FN9O3Purity:98.28% - 99.76%Color and Shape:SolidMolecular weight:665.76MT-802
CAS:<p>MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).</p>Formula:C41H41N9O8Purity:95.93% - 97%Color and Shape:SolidMolecular weight:787.82Tirabrutinib hydrochloride
CAS:<p>Tirabrutinib hydrochloride is a potent, highly selective, irreversible oral BTK inhibitor.Cost-effective and quality-assured.</p>Formula:C25H23ClN6O3Purity:99.04% - 99.27%Color and Shape:SolidMolecular weight:490.94BTK-IN-40
CAS:<p>BTK-IN-40 (compound 375) is an inhibitor of BTK.</p>Formula:C20H25N7O2Color and Shape:SolidMolecular weight:395.46Ibrutinib dimer
CAS:<p>Ibrutinib dimer is an impurity of Ibrutinib. IIbrutinib dimer is a Dimer of Ibrutinib. Ibrutinib is an irreversible Btk inhibitor (IC50: 0.5 nM).</p>Formula:C50H48N12O4Purity:98%Color and Shape:SolidMolecular weight:880.99DD 03-171
CAS:<p>Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.</p>Formula:C55H62N10O8Color and Shape:SolidMolecular weight:991.163Ibrutinib-biotin
CAS:<p>Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).</p>Formula:C56H80N12O9SPurity:98%Color and Shape:SolidMolecular weight:1097.39PROTAC BTK Degrader-5
<p>PROTAC BTK Degraders-5 (Compound 3e) is a selective Bruton's tyrosine kinase (BTK) degrader with a DC50 of 7.0 nM in JeKo-1 cells, demonstrating specificity by</p>Formula:C52H57ClFN9O6Purity:98%Color and Shape:SolidMolecular weight:958.52DBt-10
<p>DBt-10 is a potent Bruton's tyrosine kinase (BTK) degrader [1].</p>Formula:C68H86ClFN16O6Purity:98%Color and Shape:SolidMolecular weight:1277.96PROTAC BTK Degrader-9
<p>PROTACBTK Degrader-9 (compound 23) is a potent PROTACs degrader that specifically targets BTK. It effectively downregulates the RANKL-activated BTK-PLCγ2-Ca2+-NFATc1 signaling pathway. Consequently, PROTACBTK Degrader-9 inhibits osteoclastogenesis and reduces alveolar bone resorption in a mouse model of periodontitis.</p>Formula:C46H52FN13O5Molecular weight:885.41984Acalabrutinib enantiomer
CAS:<p>R-Acalabrutinib, a BTK inhibitor,enantiomer, is researched for cancer, autoimmune diseases, and inflammation.</p>Formula:C26H23N7O2Purity:97.27%Color and Shape:SolidMolecular weight:465.51PTD10
CAS:<p>PTD10, a highly potent PROTAC BTK degrader, exhibits a DC50 of 0.5 nM and a KD of 2.28 nM.</p>Formula:C49H51N11O8Purity:98%Color and Shape:SolidMolecular weight:922BTK inhibitor 17
CAS:<p>BTK inhibitor 17 is a potent irreversible BTK inhibitor (IC50 = 2.1 nM). BTK inhibitor 17 can be used in rheumatoid arthritis studies.</p>Formula:C25H24N6O3Purity:99.57% - 99.88%Color and Shape:SolidMolecular weight:456.5FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Color and Shape:LiquidPCI-33380
CAS:<p>PCI-33380 is an irreversible inhibitor of Bruton's Tyrosine Kinase.</p>Formula:C46H52BF2N11O3Purity:98%Color and Shape:SolidMolecular weight:855.8evobrutinib
CAS:<p>Evobrutinib(M2951) , also known as M-2951 and MSC-2364447C, is a highly selective inhibitor of the Bruton's tyrosine kinase (BTK), which is important in the</p>Formula:C25H27N5O2Purity:98.03% - 99.58%Color and Shape:SolidMolecular weight:429.51PROTAC BTK Degrader-8
<p>PROTACBTK Degrader-8 (compound 3) is an efficient PROTAC BTK degrader with a linker that can couple with ADC antibodies to form PAC.</p>Formula:C80H94F2N14O20P2Molecular weight:1670.62121BCPyr
CAS:<p>BCPyr is a new candidate BTK degrader ( DC 50 = 800 nM).</p>Formula:C58H65F2N11O8Color and Shape:SolidMolecular weight:1082.224PROTAC BTK Degrader-10
CAS:<p>PROTAC BTK Degrader-10 (Example 1P) is a PROTAC compound that targets BTK for degradation. It is applicable in the research of chronic lymphocytic leukemia (CLL). [Pink: ligand for target protein; Black: linker; Blue: ligand for E3 ligase Cereblon].</p>Formula:C42H49N11O4Color and Shape:SolidMolecular weight:771.91GBD-9
CAS:<p>GBD-9, a dual-mechanism degrader, effectively promotes the degradation of BTK and GSPT1 through recruitment of E3 ligase cereblon (CRBN).</p>Formula:C44H47N9O6Purity:98%Color and Shape:SolidMolecular weight:797.9BTK-IN-5
CAS:<p>BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases,</p>Formula:C23H32N4O5Color and Shape:SolidMolecular weight:444.532PROTAC BTK Degrader-2
CAS:<p>PROTAC BTK Degrader-2, a potent degrader of BTK through the PROTAC mechanism, effectively diminishes BTK protein levels [1].</p>Formula:C47H54F2N8O13Color and Shape:SolidMolecular weight:976.97PROTAC BTK Degrader-12
CAS:<p>PROTAC BTK Degrader-12 (EXAMPLE 19) is a PROTAC-based BTK degrader, featuring a structure where the BTK ligand and linker are highlighted in pink and black, the linker in black, and the VHL ligand in blue.</p>Formula:C47H54N12O4Color and Shape:SolidMolecular weight:851.01PROTAC BTK Degrader-6
CAS:<p>PROTAC BTK Degrader-6 (Compound 15), with a DC50 of 3.18 nM, exhibits anti-inflammatory properties by inhibiting NF-κB activation and suppressing the expression</p>Formula:C45H47N11O6Purity:98%Color and Shape:SolidMolecular weight:837.92PROTAC BTK Degrader-13
<p>PROTAC BTK Degrader-13 (Compound 25) is a targeted BTK PROTAC degrader with a DC50 of 0.27 μM. It inhibits BTK activity with an IC50 of 0.44 μM and suppresses IL-2-induced T cell kinase (ITK) with an IC50 of 2.16 μM. This compound also inhibits the p38 MAPK signaling pathway, thereby blocking the activation of the BCR (B cell receptor) signaling pathway. [Pink: ligand for target protein BTK ligand 15; Black: linker; Blue: ligand for E3 ligase cereblon]</p>Formula:C33H30N6O7Color and Shape:SolidMolecular weight:622.63FDU73
<p>FDU73 is a potent and selective BTK PROTAC degrader with a DC50 of 2.9 nM in JeKo-1 cells. It inhibits tumor cell proliferation and exhibits antitumor activity.</p>Color and Shape:Odour SolidPROTAC BTK Degrader-1
CAS:<p>Potent, selective oral PROTAC BTK Degrader-1; IC50: 34.51 nM (WT), 64.56 nM (BTK-481S); reduces BTK protein, inhibits tumors.</p>Formula:C43H43N9O4Color and Shape:SolidMolecular weight:749.86CNX-500
CAS:<p>CNX-500: covalent Btk inhibitor linked to biotin, IC50 0.5 nM, low effect on EGFR and Src kinases.</p>Formula:C48H68N10O9SPurity:98%Color and Shape:SolidMolecular weight:961.18SJF620 hydrochloride
CAS:<p>SJF620 hydrochloride is a PROTAC that utilizes a lenalidomide analog to recruit CRBN and ligands to target Btk, exhibiting a DC50 of 7.9 nM [1].</p>Formula:C41H45ClN8O7Purity:98%Color and Shape:SolidMolecular weight:797.3Tyrosinase-IN-16
CAS:<p>Tyrosinase-IN-16 inhibited tyrosinase.</p>Formula:C8H6BrN3SPurity:99.57%Color and Shape:SolidMolecular weight:256.12NRX-0492
CAS:<p>NRX-0492: orally active BTK degrader, induces ubiquitylation/proteasomal breakdown, potent with DC50 ≤0.2 nM, DC90 ≤0.5 nM, disrupts BCR signaling.</p>Formula:C43H51N11O6Color and Shape:SolidMolecular weight:817.94BRK inhibitor P21d hydrochloride
CAS:<p>BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.</p>Formula:C23H23ClFN7O2Color and Shape:SolidMolecular weight:483.93BTK ligand-14
<p>BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.</p>Color and Shape:Odour SolidBIIB091
CAS:<p>BIIB091 is a highly selective, reversible BTK inhibitor for treating autoimmune diseases.</p>Formula:C28H34N10O2Color and Shape:SolidMolecular weight:542.648TLT8
<p>TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.</p>Color and Shape:Odour SolidBTK inhibitor 19
CAS:<p>BTK inhibitor 19 is a highly selective, covalent BTK inhibitor ( IC 50 = 2.7 nM).</p>Formula:C25H24F3N7O3Color and Shape:SolidMolecular weight:527.508GDC-0834
CAS:<p>GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC50 of 1.1 and 5.6 μM in mouse and</p>Formula:C33H36N6O3SColor and Shape:SolidMolecular weight:596.74Anti-BTK Antibody (3G585)
<p>Anti-BTK Antibody (3G585) is an antibody targeting BTK. Anti-BTK Antibody (3G585) can be used in ELISA, IHC.</p>Color and Shape:Odour LiquidPoseltinib
CAS:<p>Poseltinib is an oral, irreversible BTK inhibitor (IC50 1.95 nM) with higher selectivity over BMX, TEC, and TXK, blocking BCR, FcR, and TLR signaling.</p>Formula:C26H26N6O3Color and Shape:SolidMolecular weight:470.52IBT6A hydrochloride
CAS:<p>IBT6A hydrochloride: Ibrutinib impurity, Btk inhibitor IC50: 0.5 nM, used in dimer/adduct synthesis.</p>Formula:C22H23ClN6OColor and Shape:SolidMolecular weight:422.91Elsubrutinib
CAS:<p>Elsubrutinib (ABBV-105) is a highly active, potent, and selective orally-administered inhibitor of Bruton's tyrosine kinase (BTK). It irreversibly inhibits the catalytic domain of BTK with an IC50 value of 0.18 μM. Elsubrutinib holds potential for the advancement of research on inflammatory diseases.</p>Formula:C17H19N3O2Color and Shape:SolidMolecular weight:297.358NX-5948
CAS:<p>NX-5948 (BTK-IN-24) is a PROTAC-type BTK degrader with anti-inflammatory and anticancer activities, inhibiting B cell activation.</p>Formula:C42H54N12O5Purity:98.29%Color and Shape:SolidMolecular weight:806.96N-piperidine Ibrutinib hydrochloride
CAS:<p>N-piperidine Ibrutinib hydrochloride is a BTK inhibitor that inhibits WT BTK and C481S BTK , which inhibits the growth and proliferation of cancer cells.</p>Formula:C22H23ClN6OPurity:98.83%Color and Shape:SolidMolecular weight:422.91Larotinib mesylate hydrate
CAS:<p>Larotinib mesylate hydrate is a potent, broad-spectrum, and orally active tyrosine kinase inhibitor (TKI), primarily targeting EGFR with an IC50 value of 0.6 nM</p>Formula:C26H36ClFN4O11S2Color and Shape:SolidMolecular weight:699.17RN486
CAS:<p>RN486 is an effective and specific BTK inhibitor (IC50: 4 nM).</p>Formula:C35H35FN6O3Purity:99.38%Color and Shape:SolidMolecular weight:606.69
